2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 17

Disentangling the Role of Hypoxia-Inducible Factor 1 and 2 in the Adaption Process of Human Microvascular Endothelial Cells to Pathophysiological Hypoxia
Abstract Number: 18

Epigallocatechin-3-Gallate (EGCG) Facilitates TAK1 Nuclear Translocation and Its Interaction with p300 to Inhibit Histone Acetylation in Human RA Synovial Fibroblasts
Abstract Number: 19

Pentagalloyl Glucose (PGG) Exhibits Anti-Rheumatic Activity in Human RA Synovial Fibroblasts and Rat Adjuvant-Induced Arthritis
Abstract Number: 20

Role of the Epigenetic Regulator EZH2 in Proinflammatory Macrophage Polarization and Signaling in Rheumatoid Arthritis
Abstract Number: 21

Pseudostarvation Using the AMPK Activator Metformin Downregulates Inflammation in Rheumatoid Arthritis Synovial Tissue
Abstract Number: 22

Expression of High Mobility Group Box 1 Protein and the Receptor for Advanced Glycation End Products in Primary Gouty Arthritis
Abstract Number: 23

Microvesicle-Associated Hsa-Mir-223-3p Is Elevated in Rheumatoid Synovial Fluid Compared with Osteoarthritis Synovial Fluid
Abstract Number: 24

Investigating the Role of Vitamin D in the Transition to Systemic Lupus Erythematosus in Individuals at Risk for the Disease
Abstract Number: 25

Attrition and Participant Characteristics in a Rheumatoid Arthritis Cohort
Abstract Number: 26

Higher Scores of Women Compared to Men for Most Clinical Measures of Rheumatoid Arthritis (RA) Status: Greater Differences for Patient Self-Report Scores Than for Rheumatologist Estimates: A Cross-Sectional 3 Center Study from Routine Care
Abstract Number: 27

Self-Reported Sedentary Behavior in Patients with Rheumatoid Arthritis
Abstract Number: 28

The Decrease over Time of Orthopaedic Surgery in Patients with Rheumatoid Arthritis Is Mainly Due to Reduced Rates Among Those with Rheumatoid Factor Positive Disease – Results from a Well Defined Area
Abstract Number: 29

Development of Multimorbidity in Patients with Newly Diagnosed Rheumatoid Arthritis – a Population-Based Study
Abstract Number: 30

Complications of Inflammatory Arthritis in First Nations and Non-First Nations Populations of Alberta, Canada
Abstract Number: 31

Risk of Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis: A Population Based Cohort Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].